Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study
verfasst von:
François Barbier, Claire Dupuis, Niccolò Buetti, Carole Schwebel, Élie Azoulay, Laurent Argaud, Yves Cohen, Vivien Hong Tuan Ha, Marc Gainnier, Shidasp Siami, Jean-Marie Forel, Christophe Adrie, Étienne de Montmollin, Jean Reignier, Stéphane Ruckly, Jean-Ralph Zahar, Jean-François Timsit, the OutcomeRéa Study Group
In this study including 391 critically ill patients with nosocomial pneumonia due to Gram-negative pathogens, combination therapy was not associated with a reduced hazard of death at Day 28 or a greater likelihood of clinical cure at Day 14. No over-risk of AKI was observed in patients receiving combination therapy.
Background
The benefits and harms of combination antimicrobial therapy remain controversial in critically ill patients with hospital-acquired pneumonia (HAP), ventilated HAP (vHAP) or ventilator-associated pneumonia (VAP) involving Gram-negative bacteria.
Methods
We included all patients in the prospective multicenter OutcomeRea database with a first HAP, vHAP or VAP due to a single Gram-negative bacterium and treated with initial adequate single-drug or combination therapy. The primary endpoint was Day-28 all-cause mortality. Secondary endpoints were clinical cure rate at Day 14 and a composite outcome of death or treatment-emergent acute kidney injury (AKI) at Day 7. The average effects of combination therapy on the study endpoints were investigated through inverse probability of treatment-weighted regression and multivariable regression models. Subgroups analyses were performed according to the resistance phenotype of the causative pathogens (multidrug-resistant or not), the pivotal (carbapenems or others) and companion (aminoglycosides/polymyxins or others) drug classes, the duration of combination therapy (< 3 or ≥ 3 days), the SOFA score value at pneumonia onset (< 7 or ≥ 7 points), and in patients with pneumonia due to non-fermenting Gram-negative bacteria, pneumonia-related bloodstream infection, or septic shock.
Results
Among the 391 included patients, 151 (38.6%) received single-drug therapy and 240 (61.4%) received combination therapy. VAP (overall, 67.3%), vHAP (16.4%) and HAP (16.4%) were equally distributed in the two groups. All-cause mortality rates at Day 28 (overall, 31.2%), clinical cure rate at Day 14 (43.7%) and the rate of death or AKI at Day 7 (41.2%) did not significantly differ between the groups. In inverse probability of treatment-weighted analyses, combination therapy was not independently associated with the likelihood of all-cause death at Day 28 (adjusted odd ratio [aOR], 1.14; 95% confidence interval [CI] 0.73–1.77; P = 0.56), clinical cure at Day 14 (aOR, 0.79; 95% CI 0.53–1.20; P = 0.27) or death or AKI at Day 7 (aOR, 1.07; 95% CI 0.71–1.63; P = 0.73). Multivariable regression models and subgroup analyses provided similar results.
Conclusions
Initial combination therapy exerts no independent impact on Day-28 mortality, clinical cure rate at Day 14, and the hazard of death or AKI at Day 7 in critically ill patients with mono-bacterial HAP, vHAP or VAP due to Gram-negative bacteria.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AIDS
Acquired immune deficiency syndrome
AKI
Acute kidney injury
aOR
Adjusted odd ratio
BMI
Body mass index
CFU
Colony-forming unit
CI
Confidence interval
CT
Computerized tomography
ECMO
Renal replacement therapy
HAP
Hospital-acquired pneumonia
ICU
Intensive care unit
IPTW
Inverse probability of treatment weighting
LOS
Length of stay
MDRB
Multidrug-resistant bacteria
MV
Mechanical ventilation
PaO2/FiO2
Arterial oxygen partial pressure/inspired fraction of oxygen
PDR
Pan-drug-resistant
PS
Propensity score
RRT
Renal replacement therapy
SAPS 2
Simplified acute physiology score 2
SOFA
Sepsis-related organ failure assessment
STROBE
Strengthening the Reporting of Observational Studies in Epidemiology
VAP
Ventilator-associated pneumonia
vHAP
Ventilated HAP
XDR
Extensively drug-resistant
Introduction
The potential benefits and harms of initial combination antimicrobial therapy remain controversial in patients with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) [1‐5]. Beyond the enhanced probability of administering at least one adequate agent in patients at-risk for multidrug-resistant bacteria (MDRB), combination therapy (usually a β-lactam plus an aminoglycoside or a fluoroquinolone) could conceptually improve bacterial clearance when both drugs are active against the causative pathogen, thereby hastening infection resolution and preventing the emergence of resistant mutants [6]. Nevertheless, most of randomized trials and observational studies addressing this issue reported no improvement in survival, treatment success rate or others patient-centered outcomes with combination therapy [7‐9], including in patients with pneumonia due to potentially difficult-to-treat pathogens such as Pseudomonas aeruginosa [10‐12]. In addition, combination therapy has been linked with an increased hazard of adverse events, especially acute kidney injury (AKI) when aminoglycosides are used as companion drugs [13, 14].
Yet, the overall quality of evidence on this question is low due to heterogeneity in study populations, pathogen distribution, and antimicrobial regimen [3, 7]. Further, most of dedicated studies enrolled a low proportion of patients with septic shock or severe comorbid conditions. To date, initial combination therapy is still recommended in the most severely ill patients with HAP or VAP, notably those infected with P. aeruginosa [4, 5]. Certain works suggest that the prognostic impact of combination therapy could depend on initial severity, with a survival benefit compared to single-drug therapy in patients with the highest baseline risk of death [15‐17] and, conversely, a deleterious effect in those with a low probability of dying at infection onset [15].
Anzeige
The primary objective of this retrospective study based on prospectively collected data was to investigate the effect of initial adequate combination therapy compared to adequate single-drug therapy on Day-28 all-cause mortality in critically ill patients with HAP, ventilated HAP (vHAP) or VAP due to Gram-negative bacteria. The secondary objectives were to appraise the impact of combination therapy on clinical cure rates at Day 14 and the hazard of death or AKI at Day 7.
Patients and methods
Study design and data source
This observational study was conducted using the OutcomeRéa prospective database fueled since 1996 by a total of 32 intensive care units (ICU) in France, including 18 ICUs located in university hospitals. The methodology implemented for data collection and quality control has been extensively described elsewhere [18]. The database protocol was submitted to the Institutional Review Board of the Clermont-Ferrand University Hospital (Clermont-Ferrand, France) who waived the need for informed consent (IRB no. 5891). The OutcomeRéa database has been approved by the French Advisory Committee for Data Processing in Health Research and registered by the French National Informatics and Liberty Commission (registration n°8999262), in compliance with French law on electronic data sources. The methods and results of this study are exposed according to the STROBE guidelines [19].
Study population and definitions
All patients with a first ICU stay between January 1st, 2008 and September 1st, 2019 were considered for enrollment in the study. Among them, we included those with a monobacterial HAP, vHAP or VAP due to Gram-negative bacteria and treated with adequate single-drug or adequate combination antimicrobial therapy at Day 0 (date of pneumonia diagnosis) and/or Day 1. Only the first pneumonia was analyzed in patients with multiple episodes during the ICU stay. Pneumonia cases involving more than one Gram-negative pathogen were not retained as each isolate may exhibit a distinct antimicrobial susceptibility phenotype, thereby confusing the categorization into adequate single-drug therapy and adequate combination therapy (see below). Given the study objectives exposed above, patients not receiving initial adequate therapy were not considered.
HAP was defined as pneumonia occurring more than 48 h after hospital admission in patients not receiving invasive mechanical ventilation (MV): this category included both ICU-acquired non-ventilator-associated pneumonia and non-ICU-acquired HAP requiring ICU admission. HAP requiring tracheal intubation and MV between Day -1 and Day 2 were defined as ventilated HAP (vHAP) [20]—hereafter, the term HAP will only refer to HAP not requiring MV. VAP were defined as pneumonia occurring in patients receiving MV for more than 48 h. HAP, vHAP and VAP episodes were prospectively entered in the database by the attending ICU physicians provided that standardized diagnostic criteria were met, that is (i) new or persistent/progressive pulmonary infiltrates on chest X-ray and/or CT scan, combined with (ii) purulent sputum or tracheal aspirates, (iii) fever or hypothermia (body temperature ≥ 38.5 °C or ≤ 36.5 °C, respectively) and/or leukocytosis or leukopenia (white blood cells count ≥ 104 mL or ≤ 4.103 mL, respectively), and (iv) a positive quantitative lower respiratory tract sample (endotracheal aspirate ≥ 105 colony-forming unit [CFU]/mL, broncho-alveolar lavage fluid ≥ 104 CFU/mL, or plugged telescopic catheter ≥ 103 CFU/mL). Only pneumonia due to a single Gram-negative pathogen were analyzed.
Anzeige
Adequate antimicrobial therapy was defined as the administration of one (single-drug group) or two (combination group) agents with in vitro activity against the causative pathogen, whatever the antimicrobial classes. For combination regimen, the companion drug was defined as the first discontinued antimicrobial (de-escalation) while the drug class pursued as definite therapy was defined as pivotal [21]. In all participating centers, the reinjection of aminoglycosides, when deemed indicated, was performed according to trough concentration monitoring.
MDR, extensively drug-resistant (XDR) and pan-drug-resistant (MDR) bacteria were defined according to the Centers for Disease Control and Prevention and the European Center for Disease Control and Prevention classification [22]. Immune deficiency was defined as any form of immunosuppression excepting HIV infection without acquired immune deficiency syndrome (AIDS) (that is, AIDS, active or recent < 5 years solid or hematological neoplasms, solid organ or bone marrow transplantation, and current or recent administration of corticosteroids [more than 0,5 mg/kg/day of equivalent prednisolone for more than 3 months] and/or other immunosuppressive drugs). Sepsis and septic shock were defined according to the Sepsis-3 criteria [23]. Pneumonia-related bloodstream infection (BSI) was defined as one or more blood cultures collected between Day -2 and Day 2 and growing the same pathogen than the one responsible for pneumonia.
The primary study endpoint was all-cause mortality at Day 28 [24]. Secondary endpoints were clinical cure rate at Day 14 and a composite outcome of death or treatment-emergent AKI at Day 7.
Clinical cure was defined as the complete resolution of all initial clinical and biological signs of pneumonia at Day 14, that is normal body temperature, white blood cell count between 4.109 and 12.109/L, increase in PaO2/FiO2 ratio ≥ 50 mmHg under MV or successful extubation, vasopressor weaning (when administered at Day 0 and/or Day 1) and, for patients with HAP, respiratory rate < 25/min if > 25/min at Day 0 and/or Day 1. Death from any cause at Day 14, bloodstream infection due the pathogen responsible for pneumonia between Day 7 and Day 14, and a lower respiratory tract sample positive with this pathogen above the significance threshold between Day 7 and Day 14 were classified as clinical failure. Patients discharged alive from the ICU before Day 14 were considered as clinically cured. AKI was defined according to the KDIGO criteria, with or without new requirement for renal replacement therapy [25]—episodes occurring between Day 1 and Day 7 were defined as treatment-emergent AKI. As early death may act as a competing event for the development of AKI at Day 7, both outcomes were analyzed as a composite endpoint, similarly to recent studies focused on major adverse kidney events [26].
Statistical analyses
Data are expressed as number (percentage) for categorical variables and median (interquartile range) for continuous variables, unless otherwise indicated. Categorical and continuous variables were compared between the single-drug and combination groups using the Fisher’s exact test or the χ2 test and the Kruskal–Wallis test or the T-test, respectively.
The adjusted odd ratios (aOR) and their 95% confidence intervals (CI) for the association between antimicrobial regimen (i.e., single drug versus combination) and the study endpoints (all-cause mortality at Day 28, clinical cure rate at Day 14, and death or treatment-emergent AKI at Day 7) were estimated using logistic regressions. Two separate approaches were used to estimate the average treatment effect of combination therapy while accounting for confounding: (i) inverse probability of treatment-weighted (IPTW) regression; and (ii) multivariable regression. Propensity scores (PS) were calculated from selected prognostically important covariates (those related to outcomes) and confounding covariates (those related to both antimicrobial regimen and outcomes) through multivariable logistic regressions (Table S1 in the Additional file 1). The concordance statistic (c-statistic) was used to test the appropriateness of the models. The IPTW were defined as the inverse of the PS for patients receiving combination therapy and 1/(1–PS) (i.e., the inverse of 1–PS) those receiving single-drug therapy. Stabilized weights (defined as the weight multiplied by the probability of receiving the treatment actually administered) were calculated from the PS [27]. After calculating the weights, absolute standardized differences were measured for each covariate to evaluate the success of the models in creating balanced cohorts (Figure S1 in the Additional file 1). Standardized differences of more than 0.1 were considered an indicative of imbalance. IPTW-adjusted Day-28 survival curves were built and compared between the two groups, with calculation of the weighted hazard ratio and its 95% CI.
The same covariates than those selected for the IPTW models were used for the multivariable regression models. Subgroup analyses based on these multivariable regression models were then performed according to the resistance phenotype of the causative pathogens (MDR or non-MDR), the pivotal β-lactam class (carbapenems or others), the companion drug class (aminoglycosides or others), the duration of combination therapy (< 3 or ≥ 3 days), the SOFA score value at pneumonia onset (< 7 and ≥ 7 points), in patients infected with non-fermenting Gram-negative bacteria, in those with pneumonia-related BSI, and in those presenting with septic shock at pneumonia onset.
A total of 488 patients with HAP or VAP due to Gram-negative bacteria and receiving initial adequate antimicrobial therapy were identified over the inclusion period, including 97 patients who were excluded owing to polymicrobial pneumonia (Figure S2 in the Additional file 1). The remaining 391 patients with mono-bacterial pneumonia were included in the study; among them, 151 (38.6%) received initial adequate single-drug therapy and 240 (61.4%) received initial adequate combination therapy. The proportion of patients treated with combination therapy decreased over the inclusion period (Table 1). The two groups did not significantly differ in terms of prevalence of chronic conditions (especially immune deficiency [overall, 23.8%] and renal comorbidities [6.4%]), SAPS 2 values at ICU admission (57 [37–64]), initial requirement for organ support (invasive mechanical ventilation, 83.4%; vasopressors, 58.3%; renal replacement therapy, 17.4%), and rate of MDRB carriage prior to pneumonia onset (11.0%) (Table 1).
Table 1
Main characteristics of the study population
All patients with pneumonia
(n = 391)
Patients treated with adequate single-drug therapy
(n = 151)
Patients treated with adequate combination therapy
(n = 240)
P-value
Admission period
2008–2011
2012–2015
2016–2019
174 (44.5)
161 (41.2)
56 (14.3)
58 (38.4)
58 (38.4)
35 (23.2)
116 (48.3)
103 (42.9)
21 (8.8)
0.0006
Male sex
281 (71.9)
103 (68.2)
178 (74.2)
0.20
Age, years
65 (54–73)
63 (53–73)
66 (55–73)
0.89
BMI, kg.m−2
24.9 (21.5–29.7)
25.1 (22.5–30)
24.8 (21.4–29.1)
0.51
Chronic diseases
Any, except immune deficiency
Hepatic
Cardiac
Respiratory
Renal
Immune deficiency
163 (41.7)
23 (5.9)
78 (19.9)
75 (19.2)
25 (6.4)
93 (23.8)
60 (39.7)
7 (4.6)
29 (19.2)
31 (20.5)
8 (5.3)
35 (23.2)
103 (42.9)
16 (6.7)
49 (20.4)
44 (18.3)
17 (7.1)
58 (24.2)
0.53
0.41
0.77
0.59
0.48
0.82
SAPS 2 at ICU admission
50 (37–64)
53 (38–64)
48 (35–64)
0.35
SOFA score at ICU admission
8 (5–11)
8 (5–11)
8 (5–11)
0.42
Organ support at ICU admissiona
Non-invasive ventilation and/or HFNO
Invasive MV
Vasopressors
ECMO
RRT
28 (7.2)
326 (83.4)
228 (58.3)
16 (4.1)
68 (17.4)
10 (6.6)
126 (83.4)
81 (53.6)
7 (4.6)
25 (16.6)
18 (7.5)
200 (83.3)
147 (61.3)
9 (3.8)
43 (17.9)
0.84
1
0.14
0.79
0.78
Sepsis at ICU admission
248 (63.4)
83 (55.0)
165 (68.8)
0.006
Septic shock at ICU admission
117 (29.9)
37 (24.5)
80 (33.3)
0.06
Antimicrobial exposure before pneumoniab
Non-antipseudomonal β-lactams
Antipseudomonal β-lactams, except carbapenems
Antipseudomonal carbapenems
Fluoroquinolones
Aminoglycosides
Glycopeptides
102 (26.1)
73 (18.7)
25 (6.4)
23 (5.9)
123 (31.5)
56 (14.3)
42 (27.8)
26 (17.2)
9 (6.0)
7 (4.6)
44 (29.1)
23 (15.2)
60 (25.0)
47 (19.6)
16 (6.7)
16 (6.7)
79 (32.9)
33 (13.8)
0.54
0.56
0.78
0.41
0.43
0.68
MDRB carriage before pneumonia
43 (11.0)
12 (7.9)
31 (12.9)
0.13
Pneumonia classification
VAP
vHAP
HAP
263 (67.3)
64 (16.4)
64 (16.4)
105 (69.5)
18 (11.9)
28 (18.6)
158 (65.8)
46 (19.2)
36 (15.0)
0.15
Pneumonia characteristics
Time from hospital admission
Time from hospital admission > 7 days
Time from ICU admission
PaO2/FiO2 < 200 mmHg c
Sepsis c
Septic shock c
SOFA score value c
ΔSOFA from Day-2 to Day 2
Pneumonia-related BSI
12 (7–22)
275 (70.3)
8 (4–15)
196 (50.1)
312 (79.8)
99 (25.3)
7 (4–9)
2 (1–5)
28 (7.2)
10 (6–20)
97 (64.2)
8 (3–13)
72 (47.7)
112 (74.2)
30 (19.9)
6 (4–9)
2 (1–4)
10 (6.6)
14 (7–23)
178 (74.2)
8 (4–15.5)
124 (51.7)
200 (83.3)
69 (28.8)
7 (4–9)
2 (1–5)
18 (7.5)
0.02
0.04
0.41
0.44
0.03
0.05
0.16
0.04
0.74
Gram-negative bacteria responsible for pneumonia
Enterobacterales
Klebsiella pneumoniae/Klebsiella oxytoca
Escherichia coli
Serratia marcescens
Klebsiella aerogenes
Enterobacter cloacae
Others
Non-fermenters
Pseudomonas aeruginosa
Stenotrophomonas maltophilia
Achromobacter spp
Acinetobacter baumannii
Haemophilus spp
MDR bacterium
XDR/PDR bacterium
207 (52.9)
60 (15.4)
57 (14.6)
45 (11.5)
13 (3.3)
9 (2.3)
23 (5.9)
170 (43.5)
150 (38.4)
10 (2.6)
6 (1.5)
4 (1.0)
14 (3.6)
76 (19.5)
8 (2.1)
91 (60.3)
24 (15.8)
22 (14.6)
28 (18.5)
6 (4.0)
2 (1.3)
9 (6.1)
52 (34.4)
44 (29.2)
3 (2.0)
4 (2.6)
1 (0.7)
8 (5.3)
24 (15.9)
3 (2.0)
116 (48.3)
36 (15.1)
35 (14.6)
17 (7.1)
7 (2.9)
7 (2.9)
14 (5.9)
118 (49.2)
106 (44.2)
7 (2.9)
2 (0.8)
3 (1.3)
6 (2.5)
52 (21.7)
5 (2.1)
0.02
0.89
1
0.0009
0.57
0.49
1
0.005
0.003
0.75
0.21
1
0.17
0.19
1
Duration of antimicrobial therapy, overall, days
8 (6–12)
7 (5–10)
8.5 (6–13)
0.04
Duration of combination therapy, days
3 (2–5)
-
3 (2–5)
-
Pivotal antimicrobial agent
Antipseudomonal penicillins ± BLI
Antipseudomonal carbapenems
Antipseudomonal cephalosporins
Non-antipseudomonal penicillins/cephalosporins
Aztreonam
Fluoroquinolones
Aminoglycosides
Cotrimoxazole
Colistin
137 (35.0)
104 (26.6)
76 (19.5)
55 (14.1)
1 (0.3)
9 (2.3)
3 (0.8)
3 (0.8)
3 (0.8)
47 (31.1)
32 (21.2)
25 (16.6)
37 (24.5)
0
3 (2.0)
3 (2.0) d
3 (2.0)
1 (0.7) e
90 (37.5)
72 (30.0)
51 (21.2)
18 (7.5)
1 (0.4)
6 (2.5)
0
0
2 (0.8)
< 0.0001
Companion antimicrobial agent
Aminoglycosides
Fluoroquinolones
Cotrimoxazole
Colistin
174 (72.5)
51 (21.3)
12 (5)
3 (1.3)
-
-
-
-
174 (72.5)
51 (21.3)
12 (5)
3 (1.3)
-
Post-pneumonia follow-up, days
31 (13–135.5)
34 (12–136)
31 (13–135)
0.87
Pneumonia outcomes
Clinical cure at Day 14
Relapse
Time to relapse, days
Superinfection
Time to superinfection, days
171 (43.7)
37 (9.5)
15 (10–18)
10 (2.6)
15.5 (9–30)
75 (49.7)
8 (5.3)
15 (7.5–18)
3 (2.0)
14 (2–15)
96 (40.0)
29 (12.1)
13 (10–18)
7 (2.9)
29 (9–37)
0.06
0.03
0.50
0.57
0.19
Treatment-emergent AKI at Day 7
Need for RRT
142 (36.3)
43 (30.3)
47 (31.1)
10 (21.3)
95 (39.6) f
33 (34.7)
0.09
0.10
MDRB carriage acquired after pneumoniab
57 (14.6)
29 (19.2)
28 (11.7)
0.04
Clostridioides difficile infection after pneumonia b
5 (1.3)
4 (2.6)
1 (0.4)
0.10
Organ support during the ICU stay
MV
Duration, days
Vasopressors
Duration, days
RRT
Duration, days
ECMO
Duration, days
376 (96.2)
18 (11–29)
308 (78.8)
7 (4–13)
144 (36.8)
8.5 (3–16)
25 (6.4)
12 (5–15)
141 (93.4)
17 (10–27)
106 (70.2)
7 (4–13)
56 (37.1)
8.5 (2.5–15.5)
9 (6.0)
11 (9–12)
235 (97.9)
19 (12–30)
202 (84.2)
7 (4–14)
88 (36.7)
8.5 (4–16)
16 (6.7)
13.5 (4.5–18.5)
0.03
0.78
0.001
0.89
0.93
0.86
0.78
0.68
ICU LOS, days
23 (14–39)
22 (13–37)
26 (15–41)
0.55
Hospital LOS, days
40 (24–69)
40.5 (22.5–70)
40 (26–69)
0.66
In-hospital death
Day 7
Day 14
Day 28
Overall
40 (10.2)
86 (22.0)
122 (31.2)
195 (49.9)
16 (10.6)
34 (22.5)
43 (28.5)
64 (42.4)
24 (10.0)
52 (21.7)
79 (32.9)
131 (54.6)
0.85
0.84
0.36
0.02
Data are exposed as number (percentage) or median (interquartile range)
cAt pneumonia onset, i.e. Day 0 (date of pneumonia diagnosis) and/or Day 1
dPneumonia due to MDR P. aeruginosa (n = 2) and MDR E. coli (n = 1)
ePneumonia due to MDR P. aeruginosa
f66/174 (37.9%) for aminoglycoside-containing combinations versus 29/66 (43.9%) for other combinations (P = 0.30)
Characteristics of pneumonia and antimicrobial therapy
The two groups were similar regarding pneumonia distribution (overall, VAP, vHAP and HAP, 67.3%, 16.4% and 16.4% of episodes, respectively), SOFA score values at pneumonia onset (7 [4‐9] points), proportion of cases with a PaO2/FiO2 ratio < 200 mmHg (50.1%), and prevalence of MDR (19.5%) and XDR/PDR (2.1%) pathogens (Table 1). Pneumonia due to P. aeruginosa or other non-fermenting Gram-negative bacteria (49.2% versus 34.4%, P = 0.005) and pneumonia-related sepsis (83.3% versus 74.2%, P = 0.03) were more common in the combination group. Pneumonia-related BSI was documented in 28 patients (7.2%).
β-lactams were prescribed as pivotal drugs in 372 patients (95.1%) (Table 1). Antipseudomonal β-lactams—especially carbapenems—were more frequently used in the combination group (P < 0.0001). Companion drugs, mostly aminoglycosides (72.5%) and fluoroquinolones (21.3%), were administered for a median duration of 3 (2–5) days. The total duration of antimicrobial therapy was longer in the combination group than in the single-drug group (8.5 [6–13] versus 7 [5–10] days, P = 0.04). Initial dosing schemes are exposed in Additional file 1: Table S2.
Impact of combination therapy on day-28 mortality
All-cause mortality rates at Day 28 were 28.5% and 32.9% in the single-drug and combination groups, respectively (P = 0.36) (Table 1). The cumulative survival overtime did not significantly differ between the two groups (IPT-weighted hazard ratio, 1.07; 95% CI, 0.74–1.55; P = 0.71) (Fig. 1). After adjustment on potential confounders (Additional file 1: Table S1), combination therapy exerted no independent effect on this outcome, in IPTW analysis (aOR, 1.14; 95% CI, 0.73–1.77; P = 0.56) as in multivariable regression (aOR, 1.18; 95% CI, 0.73–1.92; P = 0.50) (Fig. 2). This lack of association between combination therapy and Day-28 mortality was confirmed in subgroup analyses focused on patients with non-carbapenem-based regimen, aminoglycoside as companion drug, combination therapy administered for ≥ 3 days, pneumonia due to MDR and/or non-fermenting Gram-negative bacteria, and a SOFA score value ≥ 7 or septic shock at pneumonia onset (Table 2).
Fig. 1
IPTW-adjusted cumulative survival at Day 28 in patients treated with single-drug versus combination therapy. IPTW, inverse probability of treatment weighting; HR, hazard ratio; CI, confidence interval
Fig. 2
Impact of combination therapy on study endpoints: results of IPTW and multivariable regression analyses (whole study population). Regression models were adjusted on inclusion period, the SAPS 2 score value at intensive care unit admission, prior chronic diseases, prior immune deficiency, time from hospital admission to pneumonia, pneumonia type, and the SOFA score value at pneumonia onset. In addition, (i) the model focused on clinical cure at Day 14 was adjusted on colonization with MDR Gram-negative bacteria, and (ii) the model focused on death or treatment-emergent AKI at Day 7 was adjusted on diabetes mellitus, prior contrast-enhanced computerized tomography and/or angiography, and prior aminoglycoside and/or glycopeptide exposure. See Additional file 1: Table S1 and Figure S1. OR, odds ratio; CI, confidence interval; IPTW, inverse probability of treatment weighting; AKI, acute kidney injury
Table 2
Impact of combination therapy on study endpoints: results of subgroup analyses
Patient subpopulations
Mortality at Day 28
Clinical cure at Day 14
Death or AKI at Day 7
aOR (95% CI)
P-value
aOR (95% CI)
P-value
aOR (95% CI)
P-value
Pneumonia due to MDR Gram-negative bacteria
0.88 (0.31–2.53)
0.82
1.52 (0.42–5.41)
0.52
1.82 (0.57–5.77)
0.31
Pneumonia due to non-MDR Gram-negative bacteria
1.22 (0.69–2.16)
0.50
0.76 (0.46–1.27)
0.30
0.96 (0.55–1.66)
0.88
Pneumonia due to no-fermenting Gram-negative bacteria
0.73 (0.30–1.73)
0.47
1.13 (0.49–2.56)
0.78
1.36 (0.54–3.46)
0.52
Carbapenem-based regimen
1.14 (0.45–2.88)
0.78
0.53 (0.20–1.41)
0.21
1.51 (0.45–5.05)
0.50
Non-carbapenem-based regimen
1.09 (0.60–1.99)
0.77
0.99 (0.57–1.73)
0.98
0.81 (0.46–1.44)
0.48
Aminoglycoside-containing regimen
1.23 (0.74–2.06)
0.42
0.78 (0.48–1.26)
0.31
1.05 (0.62–1.76)
0.86
Non-aminoglycoside-containing regimen
1.01 (0.48–2.12)
0.98
0.76 (0.39–1.47)
0.42
1.26 (0.65–2.46)
0.49
Combination therapy < 3 days
1.04 (0.58–1.87)
0.90
1.12 (0.64–1.95)
0.70
1.00 (0.55–1.80)
0.99
Combination therapy ≥ 3 days
1.34 (0.76–2.39)
0.32
0.59 (0.35–1.01)
0.05
1.18 (0.68–2.05)
0.55
SOFA score value < 7 at pneumonia onset
1.43 (0.65–3.12)
0.37
0.79 (0.42–1.50)
0.47
1.11 (0.56–2.18)
0.77
SOFA score value ≥ 7 at pneumonia onset
1.01 (0.54–1.91)
0.97
0.89 (0.43–1.84)
0.76
1.02 (0.50–2.09)
0.95
Septic shock at pneumonia onset
1.40 (0.49–3.99)
0.53
0.60 (0.19–1.88)
0.38
2.22 (0.65–7.62)
0.21
Pneumonia-related BSI a
1.49 (0.29–7.74)
0.64
0.50 (0.10–2.43)
0.39
0.80 (0.17–3.77)
0.78
Multivariate regression models were adjusted on inclusion period, the SAPS 2 score value at intensive care unit admission, prior chronic diseases, prior immune deficiency, time from hospital admission to pneumonia, pneumonia type, and the SOFA score value at pneumonia onset. In addition, (i) the model focused on clinical cure at Day 14 was adjusted on colonization with MDR Gram-negative bacteria, and (ii) the model focused on death or treatment-emergent AKI at Day 7 was adjusted on diabetes mellitus, prior contrast-enhanced computerized tomography and/or angiography, and prior aminoglycoside and/or glycopeptide exposure. See Additional file 1: Table S1 and Figure S1
aUnivariate analysis due to the low number of patients with pneumonia-related BSI
×
×
Anzeige
Impact of combination therapy on clinical cure at day 14
There was a trend toward a higher clinical cure rate at Day 14 in patients receiving single-drug therapy when compared to those treated with combination therapy (49.7% versus 40.0%, P = 0.06) (Table 1). Combination therapy was not independently associated with this endpoint, in IPTW analysis (aOR, 0.79; 95% CI 0.53–1.20; P = 0.27) as in multivariable regression (aOR, 0.82; 95% CI 0.51–1.29; P = 0.38) (Fig. 1). In subgroup analyses, receiving combination therapy for ≥ 3 days was negatively linked with the likelihood of clinical cure at Day 14 (Table 2). No association was observed between combination therapy and this endpoint in all other subgroups, including in patients infected with MDR and/or non-fermenting Gram-negative bacteria (Table 2).
Impact of combination therapy on the hazard of death or treatment-emergent AKI at day 7
The cumulative incidences of treatment-emergent AKI (39.6% versus 31.1%, P = 0.09) and death (10.0% versus 10.6%, P = 0.85) at Day 7 did not significantly differ between the combination and the single-drug group. In the combination group, the cumulative incidence of AKI was similar in patients receiving aminoglycosides and those receiving other companion drugs (66/174 = 37.9% versus 29/66 = 43.9%, P = 0.30) (Table 1). Combination therapy exerted no independent effect on the likelihood of AKI or death at Day 7, in IPTW analysis (aOR, 1.07; 95% CI 0.71–1.63; P = 0.73) as in multivariable regression (aOR, 1.10; 95% CI, 0.68–1.77; P = 0.70) (Fig. 1). Likewise, combination therapy was not associated with this composite outcome in analyses restricted to patients receiving an aminoglycoside as companion drug, those receiving combination for ≥ 3 days, and in those with a SOFA score value ≥ 7 points or septic shock at pneumonia onset (Table 2).
Discussion
In this multicenter study including 391 critically ill patients with HAP, vHAP or VAP due to Gram-negative pathogens, the initial administration of adequate combination therapy was not independently associated with a reduced hazard of death at Day 28 or a greater likelihood of clinical cure at Day 14 when compared to adequate single-drug regimen. No over-risk of treatment-emergent AKI was observed in patients receiving combination therapy.
A meta-analysis of randomized controlled trials published fifteen years ago failed to demonstrate a benefit of initial combination therapy on short-term survival in patients with suspected VAP [7]. Yet, most of trials included a low proportion of patients with potentially difficult-to-treat pathogens (namely, non-fermenting and/or MDR Gram-negative bacteria) and used heterogeneous definitions for septic shock. Moreover, no subgroup analysis was performed in patients with microbiologically documented VAP and receiving adequate single-drug or combination therapy [7]. A more recent randomized trial showed no difference on Day-28 mortality in patients with suspected VAP treated with meropenem plus ciprofloxacin versus meropenem alone; however, a large subset of the study population had either no confirmed VAP or VAP involving pathogens without therapeutic issue (e.g., oropharyngeal flora) [8]. Also, the potential effect of combination therapy was not investigated according to baseline severity [8]. Another trial comparing meropenem plus moxifloxacin versus meropenem alone in patients with sepsis found no difference on survival or the course of organ failures, including in the subgroup with pneumonia; nevertheless, only one third of patients had a microbiologically confirmed infection at enrollment [28]. Overall, while the delayed administration of active antimicrobials has been repeatedly associated with impaired outcomes in critically ill patients with culture-proven HAP or VAP [29, 30], it remains unsettled whether adequate combination therapy may improve survival in this population when compared to adequate single-drug therapy. This may contribute to intensivists’ reluctance for de-escalation and cessation of the companion drug in this situation [31]. Evidence on this issue is almost inexistent for patients with vHAP, who consistently exhibit a worse prognosis than those with VAP or HAP [32‐34]. In our study, receiving combination therapy was not associated with Day-28 mortality, in univariate analyses as after adjustment on potential confounders. These results indicate that dual-active regimen provide no survival gain in patients with nosocomial pneumonia due to Gram-negative pathogens, notably in those with vHAP. This is consistent with current guidelines advocating empirical combination therapy in severely ill patients with HAP or VAP and risk factors for MDR Gram-negative pathogens then de-escalation to a single-drug regimen once susceptibility test results become available [4, 5].
Anzeige
The prevalence of sepsis and septic shock at pneumonia onset was higher in the combination group, which may merely reflect that intensivists were more prone to prescribe initial—that is, most often empirical—combination therapy in patients with these conditions, in concordance with academic recommendations [4, 5]. However, whether the most severely ill patients may still benefit from combination therapy is an unsolved question [1, 2]. A meta-analysis of randomized trials including only patients with sepsis—related or not to pulmonary infections—found no survival improvement with combination therapy; however, the quantity and quality of data was low, precluding any definite conclusion to be drawn [3]. Besides, certain observational studies reported improved outcomes with combination therapy in patients at high baseline risk for death [15, 16, 35]. The subgroup analyses performed as part of our work suggest that combination therapy exerts no effect on survival in patients with septic shock, severe hypoxemia or, more globally, high SOFA score values at pneumonia onset provided that the pivotal β-lactam is fully active against the causative Gram-negative pathogen. A major aim of empirical combination therapy is to increase the likelihood of administering at least one agent with in vitro activity against the causative pathogen [4, 5, 10, 36]. Hence, our data do not support the use of empirical combination therapy in patients without risk factors for pneumonia due to MDR pathogens, including in those with the most severe presentations. Adequately powered prospective trials are warranted to confirm these results and reinforce antimicrobial stewardship guidelines in such situations.
This lack of survival impact could plausibly result from a counterbalance between a benefit in terms of clinical response and an increased incidence of severe antimicrobial-related adverse events—especially AKI when nephrotoxic agents are administered as companion drugs [13, 14, 37]. Our data argue against this hypothesis. First, and in concordance with the available evidence [7, 10, 12, 38], combination therapy was not associated with a greater likelihood of clinical cure, including in patients infected with non-fermenting Gram-negative pathogens or in those receiving second agents with substantial lung bioavailability (i.e., fluoroquinolones or cotrimoxazole). Conversely, there was a trend toward a higher clinical cure rate in the single-drug group; moreover, receiving combination therapy for 3 days or more was negatively linked with the likelihood of clinical cure in adjusted analyses. Yet, these findings may merely reflect intensivists’ decision to continue the companion drug in patients with unfavorable clinical response at Day 3. Next, the crude incidence of treatment-emergent AKI was slightly higher in the combination group, which was likely due to a more common use of dual regimen in the most severe patients—i.e. those with the more pronounced hazard of renal failure, independently of drug exposure. However, combination therapy with an aminoglycoside was not associated with this outcome after careful adjustment on potential confounders, including severity indexes and other predisposing factors for AKI. This result may ensue from the routine use of once-daily administration, monitoring of trough concentrations, and other measures to prevent aminoglycoside-induced nephrotoxicity in the participating ICUs [39‐41].
This work has limitations. First, this is an observational study. Therefore, despite the use of prospectively collected data and PS-adjusted analyses, residual confounding on the outcomes of interest cannot be firmly ruled out. Second, the potential impact of dosing schemes on the study endpoints was not investigated due to the limited subset of patients with each given regimen. Also, information on therapeutic drug monitoring was not available in the database. However, initial daily doses of pivotal and companion drugs were consistent with current standards and guidelines for optimized antimicrobial pharmacokinetic in critically ill individuals (Additional file 1: Table S2) [2, 4, 5]. Along this line, single-drug therapies with an aminoglycoside or colistin were considered as adequate when fully active in vitro though the pulmonary diffusion of these agents may be suboptimal with low-dose regimen. Fourth, the outcome effect of combination therapy in pneumonia involving XDR or PDR Gram-negative bacteria could not be appraised due to the very low number of patients infected with such pathogens—dedicated studies are warranted to solve this question, especially with novel β-lactams [35, 42, 43]. Fifth, we compared the hazard of AKI between patients with combination and single-drug therapy; yet, adding a second agent to an effective pivotal drug may cause other antimicrobial-related side-effects that were not investigated in our work [44, 45]. Sixth, we only studied the first pneumonia in patients with multiple episodes during the ICU stay. Whether patients with pneumonia relapse or second VAP may benefit from combination therapy remains to be explored. Lastly, we did not appraise the impact of combination therapy in patients with HAP managed outside the ICU.
Conclusion
When compared to initial adequate single-drug regimen, initial adequate combination therapy exerts no independent impact on survival or clinical success rate in critically ill patients with a first episode of mono-bacterial HAP, vHAP or VAP due to Gram-negative pathogens, including in those with pneumonia due to non-fermenting bacteria or presenting with septic shock, severe hypoxemia or high SOFA score values at infection onset.
Acknowledgements
None.
Declarations
Ethical approval and consent to participate
The OutcomeRéa database protocol was submitted to the Institutional Review Board of the Clermont-Ferrand University Hospital (Clermont-Ferrand, France) who waived the need for informed consent (IRB No. 5891).
Consent for publication
Not applicable.
Competing interests
F. B. declares having received lecture and consulting fees from MSD, lecture fees for BioMérieux and conference invitation from Pfizer, not related to the submitted work. J.-F. T. declares having received consulting fees from Gilead, MSD, Pfizer, BioMérieux and Roche diagnostic, and lecture fees from MSD, Pfizer, Shionogi, BioMérieux, Qiagen, Mundipharma and Gilead, not related to the submitted work. J.-R. Z. declares having received consulting fees and conference invitation from MSD, consulting fees, lecture fees and conference invitations from Pfizer, lecture Fees from Advanz-Pharma and Shionogui, and conference invitations from Biomérieux and Gilead, not related to the submitted work. E. A. is Associate Editor of Critical Care. Other authors declare having no potential conflict of interest related to the submitted work.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study
verfasst von
François Barbier Claire Dupuis Niccolò Buetti Carole Schwebel Élie Azoulay Laurent Argaud Yves Cohen Vivien Hong Tuan Ha Marc Gainnier Shidasp Siami Jean-Marie Forel Christophe Adrie Étienne de Montmollin Jean Reignier Stéphane Ruckly Jean-Ralph Zahar Jean-François Timsit the OutcomeRéa Study Group
Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.
Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.
Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.
Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.
Update AINS
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
